KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $3.4 million.

  • Emergent BioSolutions' Capital Expenditures fell 41.38% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 64.42%. This contributed to the annual value of $22.9 million for FY2024, which is 55.62% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Capital Expenditures stood at $3.4 million, which was up 17.24% from $2.9 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Capital Expenditures high stood at $179.4 million for Q3 2022, and its period low was $1.7 million during Q4 2024.
  • Over the past 3 years, Emergent BioSolutions' median Capital Expenditures value was $5.8 million (recorded in 2024), while the average stood at $7.7 million.
  • In the last 5 years, Emergent BioSolutions' Capital Expenditures surged by 225.00% in 2022 and then plummeted by 92.98% in 2023.
  • Emergent BioSolutions' Capital Expenditures (Quarterly) stood at $45.8 million in 2021, then skyrocketed by 225.00% to $179.4 million in 2022, then slumped by 92.98% to $11.4 million in 2023, then plummeted by 85.09% to $1.7 million in 2024, then plummeted by 41.38% to $3.4 million in 2025.
  • Its Capital Expenditures was $3.4 million in Q3 2025, compared to $2.9 million in Q2 2025 and $3.6 million in Q1 2025.